HC Wainwright Expects Weaker Earnings for COMPASS Pathways

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of COMPASS Pathways in a report issued on Tuesday, July 15th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.38) per share for the quarter, down from their previous estimate of ($0.34). HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $0.04 EPS and FY2029 earnings at $1.59 EPS.

CMPS has been the topic of a number of other research reports. Evercore ISI restated an "in-line" rating and issued a $6.00 price target (down previously from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $17.00.

COMPASS Pathways Stock Performance

NASDAQ CMPS traded up $0.42 on Thursday, hitting $4.30. 4,573,064 shares of the company's stock were exchanged, compared to its average volume of 1,306,083. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. The firm's 50-day moving average price is $3.95 and its two-hundred day moving average price is $3.78. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.54. The firm has a market cap of $402.31 million, a price-to-earnings ratio of -2.16 and a beta of 2.12.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03.

Hedge Funds Weigh In On COMPASS Pathways

Several large investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC increased its stake in shares of COMPASS Pathways by 21.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock valued at $61,000 after purchasing an additional 2,840 shares during the period. Flagship Harbor Advisors LLC increased its stake in shares of COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after purchasing an additional 3,134 shares during the period. GAMMA Investing LLC increased its stake in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after purchasing an additional 5,003 shares during the period. Kennedy Capital Management LLC increased its stake in shares of COMPASS Pathways by 22.8% in the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after purchasing an additional 6,297 shares during the period. Finally, Barclays PLC increased its stake in shares of COMPASS Pathways by 2.1% during the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after acquiring an additional 8,718 shares during the period. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.